On the public citation graph

Do Firms Respond to Peer Disclosures? Evidence from Disclosures of Clinical Trial Results

https://doi.org/10.2308/tar-2019-0137
0 signed · 74 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1007/s11142-011-9165-4openalex-snapshot
The effect of stock price on discretionary disclosure
inferredcites →https://doi.org/10.1016/0165-4101(81)90003-3openalex-snapshot
Intra-industry information transfers associated with earnings releases
inferredcites →https://doi.org/10.1016/0165-4101(83)90011-3openalex-snapshot
Discretionary disclosure
inferredcites →https://doi.org/10.1016/0165-4101(90)90021-uopenalex-snapshot
Information quality and discretionary disclosure
inferredcites →https://doi.org/10.1016/j.jacceco.2004.04.002openalex-snapshot
Economic consequences of SEC disclosure regulation: evidence from the OTC bulletin board
inferredcites →https://doi.org/10.1016/j.jacceco.2005.01.002openalex-snapshot
The economic implications of corporate financial reporting
inferredcites →https://doi.org/10.1016/j.jacceco.2006.05.001openalex-snapshot
The informativeness of earnings and management's issuance of earnings forecasts
inferredcites →https://doi.org/10.1016/j.jacceco.2010.10.006openalex-snapshot
Is silence golden? An empirical analysis of firms that stop giving quarterly earnings guidance
inferredcites →https://doi.org/10.1016/j.jacceco.2011.09.005openalex-snapshot
Measuring Securities Litigation Risk
inferredcites →https://doi.org/10.1016/j.jacceco.2017.03.005openalex-snapshot
When does the peer information environment matter?
inferredcites →https://doi.org/10.1016/j.jacceco.2020.101364openalex-snapshot
Peer Effects in Corporate Disclosure Decisions
inferredcites →https://doi.org/10.1016/j.jfineco.2013.03.012openalex-snapshot
Externalities of public firm presence: Evidence from private firms' investment decisions
inferredcites →https://doi.org/10.1016/s0165-1765(03)00032-6openalex-snapshot
Interaction terms in logit and probit models
inferredcites →https://doi.org/10.1056/nejmsa1012065openalex-snapshot
The ClinicalTrials.gov Results Database — Update and Key Issues
inferredcites →https://doi.org/10.1056/nejmsa1409364openalex-snapshot
Compliance with Results Reporting at ClinicalTrials.gov
inferredcites →https://doi.org/10.1056/nejmsr1414226openalex-snapshot
The Proposed Rule for U.S. Clinical Trial Registration and Results Submission
inferredcites →https://doi.org/10.1093/rfs/13.3.479openalex-snapshot
Forcing Firms to Talk: Financial Disclosure Regulation and Externalities
inferredcites →https://doi.org/10.1093/rfs/hhr011openalex-snapshot
Growing Out of Trouble? Corporate Responses to Liability Risk
inferredcites →https://doi.org/10.1111/1475-679x.00043openalex-snapshot
Earnings Performance and Discretionary Disclosure
inferredcites →https://doi.org/10.1111/1911-3846.12758openalex-snapshot
Regulatory Approval and Biotechnology Product Disclosures*†
inferredcites →https://doi.org/10.1111/j.1368-423x.2004.00123.xopenalex-snapshot
The behaviour of the maximum likelihood estimator of limited dependent variable models in the presence of fixed effects
inferredcites →https://doi.org/10.1111/j.1475-679x.2004.00140.xopenalex-snapshot
Competitive Costs of Disclosure by Biotech IPOs
inferredcites →https://doi.org/10.1111/j.1475-679x.2005.00174.xopenalex-snapshot
The Association between Outside Directors, Institutional Investors and the Properties of Management Earnings Forecasts
inferredcites →https://doi.org/10.1111/j.1475-679x.2005.00177.xopenalex-snapshot
The Association between Corporate Boards, Audit Committees, and Management Earnings Forecasts: An Empirical Analysis
inferredcites →https://doi.org/10.1111/j.1475-679x.2011.00434.xopenalex-snapshot
How Effective Is Internal Control Reporting under SOX 404? Determinants of the (Non‐)Disclosure of Existing Material Weaknesses
inferredcites →https://doi.org/10.1111/j.1911-3846.2011.01070.xopenalex-snapshot
Interactive Discretionary Disclosures*
inferredcites →https://doi.org/10.1162/00335530360698478openalex-snapshot
When Does the Market Matter? Stock Prices and the Investment of Equity-Dependent Firms
inferredcites →https://doi.org/10.1177/031289629702200201openalex-snapshot
Competitive Disadvantage and Discretionary Disclosure in Industries
inferredcites →https://doi.org/10.1515/9781400829828openalex-snapshot
Mostly Harmless Econometrics
inferredcites →https://doi.org/10.2139/ssrn.3533305openalex-snapshot
Consequences of Disclosing Clinical Trial Results: Evidence from the Food and Drug Administration Amendments Act
inferredcites →https://doi.org/10.2307/2298123openalex-snapshot
Identification of Endogenous Social Effects: The Reflection Problem
inferredcites →https://doi.org/10.2307/2490910openalex-snapshot
Disclosure of Nonproprietary Information
inferredcites →https://doi.org/10.2307/2490919openalex-snapshot
Earnings Volatility and Voluntary Management Forecast Disclosure
inferredcites →https://doi.org/10.2307/2491279openalex-snapshot
Shareholder Litigation and Corporate Disclosures
inferredcites →https://doi.org/10.2307/2491386openalex-snapshot
Why Firms Voluntarily Disclose Bad News
inferredcites →https://doi.org/10.2308/acch.2010.24.4.525openalex-snapshot
Are Revisions to SFAS No. 5 Needed?
inferredcites →https://doi.org/10.2308/accr-10033openalex-snapshot
Determinants of Disclosure Noncompliance and the Effect of the SEC Review: Evidence from the 2006 Mandated Compensation Disclosure Regulations
inferredcites →https://doi.org/10.2308/accr-50853openalex-snapshot
Noncompliance with Mandatory Disclosure Requirements: The Magnitude and Determinants of Undisclosed Permanently Reinvested Earnings
inferredcites →https://doi.org/10.2308/accr-51379openalex-snapshot
Cost of Capital Free-Riders
inferredcites →https://doi.org/10.2308/accr-51558openalex-snapshot
Product Market Competition and Managerial Disclosure of Earnings Forecasts: Evidence from Import Tariff Rate Reductions
inferredcites →https://doi.org/10.2308/accr-52056openalex-snapshot
Technological Peer Pressure and Product Disclosure
inferredcites →https://doi.org/10.2308/atax-50458openalex-snapshot
Firm and Investor Responses to Uncertain Tax Benefit Disclosure Requirements
inferredcites →https://doi.org/10.2308/tar-2019-0433openalex-snapshot
When You Talk, I Remain Silent: Spillover Effects of Peers' Mandatory Disclosures on Firms' Voluntary Disclosures
inferredcites →https://doi.org/10.2308/tar-2019-1050openalex-snapshot
Deterrent Disclosure
inferredcites →https://doi.org/10.2308/tar-9706165837openalex-snapshot
Determinants of management forecast precision.
inferredcites →https://doi.org/10.3810/pgm.2011.09.2475openalex-snapshot
Key Concepts of Clinical Trials: A Narrative Review

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.3459511openalex-extracted
Information Transparency in Drug Development: Evidence from Mandatory Disclosure of Clinical Trials
inferred← citeshttps://doi.org/10.2139/ssrn.4422628openalex-extracted
With a Grain of Salt: Uncertain Veracity of External News and Firm Disclosures
inferred← citeshttps://doi.org/10.2139/ssrn.4500800openalex-extracted
inferred← citeshttps://doi.org/10.2139/ssrn.4580204openalex-extracted
Corporate R&D Investments Following Competitors’ Voluntary Disclosures: Evidence from the Drug Development Process
inferred← citeshttps://doi.org/10.2139/ssrn.4674743openalex-extracted
Does ESG Reporting Matter for Shareholder Value? Evidence from Mandatory ESG Regulations in India
inferred← citeshttps://doi.org/10.2139/ssrn.4810437openalex-extracted
Burdening the Young: Life Cycle Effects of Mandatory Disclosure on Investment
inferred← citeshttps://doi.org/10.2139/ssrn.4813885openalex-extracted
Biotech IPOs and Drug Development Disclosure
inferred← citeshttps://doi.org/10.1002/mde.3839openalex-snapshot
Peer effect of proprietary information: A cost–benefit analysis of customer information disclosure
inferred← citeshttps://doi.org/10.1016/j.cjar.2024.100375openalex-snapshot
Peer effect on climate risk information disclosure
inferred← citeshttps://doi.org/10.1016/j.irfa.2025.104160openalex-snapshot
Disrupting political ties, enhancing transparency: China's anti-corruption campaign and corporate R&D disclosure
inferred← citeshttps://doi.org/10.1016/j.jacceco.2024.101720openalex-snapshot
Measuring innovation and navigating its unique information issues: A review of the accounting literature on innovation
inferred← citeshttps://doi.org/10.1016/j.jacceco.2025.101802openalex-snapshot
With a Grain of Salt: Investor Reactions to Uncertain News and (Non)disclosure
inferred← citeshttps://doi.org/10.1016/j.respol.2024.105112openalex-snapshot
Timing, modifications, and tenor of firms' mandatory R&D disclosures: The role of competition
inferred← citeshttps://doi.org/10.1038/s41598-023-39301-4openalex-snapshot
New drugs and stock market: a machine learning framework for predicting pharma market reaction to clinical trial announcements
inferred← citeshttps://doi.org/10.1080/21697213.2026.2707818openalex-snapshot
Learn from the neighbours: regional peer effect in climate transition risk information disclosure
inferred← citeshttps://doi.org/10.1111/1475-679x.12509openalex-snapshot
Corporate R&D Investments Following Competitors’ Voluntary Disclosures: Evidence from the Drug Development Process
inferred← citeshttps://doi.org/10.1111/jbfa.70005openalex-snapshot
Does ESG Reporting Matter for Shareholder Value?—Evidence on Mandatory ESG Regulations in India
inferred← citeshttps://doi.org/10.1142/s1094406025410082openalex-snapshot
Positive and Negative Peer Effects of ESG Disclosure: Evidence from China’s Selective Mandatory Disclosure Regime
inferred← citeshttps://doi.org/10.2139/ssrn.4823172openalex-snapshot
Peer Effects of Price Transparency
inferred← citeshttps://doi.org/10.2139/ssrn.5492586openalex-snapshot
(Pre-)Trends in Accounting Research
inferred← citeshttps://doi.org/10.2139/ssrn.5710162openalex-snapshot
Can Transparency Reduce Drug Costs?
inferred← citeshttps://doi.org/10.2139/ssrn.5895603openalex-snapshot
Strategic Disclosure in R&D Races: Theory and Evidence
inferred← citeshttps://doi.org/10.2139/ssrn.6363023openalex-snapshot
Spillover Effects in ESG Disclosure
inferred← citeshttps://doi.org/10.2139/ssrn.6437162openalex-snapshot
Trust and Credibility in Sustainability Reporting
inferred← citeshttps://doi.org/10.2139/ssrn.6516799openalex-snapshot
Transparency and the Allocation of Control Rights: Evidence from the 2017 FDA Disclosure Mandate
inferred← citeshttps://doi.org/10.2139/ssrn.6627299openalex-snapshot
Spillover Effects in ESG Disclosure
inferred← citeshttps://doi.org/10.2139/ssrn.7181978openalex-snapshot
Peer Effects of Supplier Finance Program Disclosures: Evidence from ASU 2022-04
inferred← citeshttps://doi.org/10.2139/ssrn.7595518openalex-snapshot
Are Aggregate Industry Benchmarks Substitutes or Complements to Firm Disclosures? Evidence from the Stoppage of Government Current Industrial Reports
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.